TORONTO, May 02, 2023 PharmaTher Holdings Ltd. , a specialty pharmaceutical company, today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration for. | May 2, 2023
TORONTO, March 29, 2023 PharmaTher Holdings Ltd. , a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration for advancing. | March 29, 2023
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson s Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine) for Parkinson’s disease under the 505(b)(2) regulatory pathway .
PharmaTher Holdings Announces Grant of U S Patent Covering Ketamine for Parkinson s Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.